Navigation Links
ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Date:9/9/2009

RANCHO CORDOVA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the fourth quarter and all of fiscal 2009.

For the quarter ended June 30, 2009, the Company reported revenues of $4.0 million. This compares with revenues of $7.2 million in the fourth quarter a year ago. As the Company indicated previously, revenues in the fourth quarter of fiscal 2009 were impacted by several factors, including delays in customer capital equipment purchases of its BioArchive((R)) System and reduced sales of AXP(TM) AutoXpress(TM) (AXP(TM)) bag sets due to the timing of orders from GE Healthcare. The Company expects these AXP orders will be recovered during the first two quarters of fiscal 2010.

Total disposable revenues were $2.2 million versus $4.2 million in the fourth quarter of fiscal 2008. Disposable revenues in the fourth quarter of fiscal 2009 were impacted by the factors outlined above, offset by revenues from sales of disposables for the Company's MarrowXpress(TM), or MXP(TM), which was launched in mid-fiscal 2009.

The company reported a net loss of $3.1 million, or $0.05 per share, versus a net loss of $2.5 million, or $0.04 per share, in the same period a year ago. As the Company indicated in its press release of August 6, 2009, the loss in the fourth quarter of fiscal 2009 included a number of non-recurring costs. They totaled approximately $1.8 million, including non-cash charges of approximately $0.9 million. Non-recurring charges included $0.8 million in reserves related to the transition to an upgraded AXP device and disposable as well as write-downs of obsolete inventory and tooling at AXP bag set suppliers. Non-recurri
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... --  HX360 today announced that sixteen companies have ... Challenge competition. These companies, selected from a field ... one of four finalists to present their solutions live ... venture capitalists during the Innovation Challenge event. ... 2015 HIMSS Annual Conference & Exhibition, McCormick Place in ...
(Date:3/5/2015)... 05, 2015 BioPlus Specialty Pharmacy (BioPlus) ... of Vice President of Managed Care. In this role, ... one of the nation’s leading specialty pharmacies. , Damm, ... years of specialty pharmacy and biotech experience to his ... Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to working in ...
(Date:3/5/2015)... and TORONTO , March ... APS), a clinical-stage company developing new therapeutics and molecular ... announced that William G. Rice , Ph.D., Chairman, ... upcoming 27th Annual ROTH Conference on Tuesday, March 10 ... Ritz Carlton, Laguna Niguel, CA. ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, ... of Action" at the Annual Research Symposium of the ... October 21, 2010.   (Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO ... Dr. Harman has presented at more than 40 veterinary ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, ... for its CYT387 JAK1/JAK2 inhibitor program demonstrating that ... profile which may provide significant clinical advantages. CYT387 ... clinical study at Mayo Clinic in patients with ...
... RALEIGH, NC and QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ ... of Medicago Inc. (TSX: MDG), a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... U.S. Senator Kay Hagan (D-NC) and U.S. Congressman ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... time, researchers have inhibited the development of epilepsy after a ... signaling pathways in the brain, neurology researchers found that they ... , "We have shown that there is a window ... that epilepsy will develop," said one of the lead researchers, ...
... Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ... that a single drug can rebuild damaged muscle in ... two human forms of muscular dystrophy. This advance, which ... from a research collaboration that began several years ago ...
... What is more, a newt can also completely repair damage ... Heart and Lung Research in Bad Nauheim have now started ... regenerate and have discovered the remarkable plasticity of newt heart ... this ability, the findings could contribute to new cell therapies ...
Cached Biology News:Gene therapy inhibits epilepsy in animals 2Scientists show drug can counteract muscular dystrophy in mice 2Newts which regrow their hearts 2
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
Biology Products: